Melasma Clinical Trial
Official title:
Comparing the Efficacy and Safety of Combined Glycolic Acid and Salicylic Acid Peel Versus Glycolic Acid Peel Alone in the Treatment of Melasma: A Split Face Study
The aim of this pilot study is to conduct a controlled comparison of the efficacy and safety of a combination peel (glycolic acid and salicylic acid) as compared to glycolic acid peel alone in the treatment of melasma. Our primary outcome is objective improvement in pigmentation as evaluated using a colorimeter. Our secondary outcomes are subjective improvement using the Melasma Area and Severity Index (MASI) and Patient and Physician Global assessment, as well as assessment of treatment tolerability and patient satisfaction.
Melasma is an acquired form of hyperpigmentation that is seen most commonly on the face,
characterized by symmetrically distributed brown patches of variable darkness. The
cosmetically unattractive nature of this disorder has been shown to negatively affect a
patient's quality of life. Unfortunately, the treatment of melasma is challenging and often
disappointing. Treatment includes a combination approach with strict sun protection, cosmetic
camouflage, topical lightening agents, laser therapy, and chemical peels.
Today, the investigators define chemical peeling as the application of chemical exfoliating
agents to the skin, which results in destruction of one or more parts of the epidermis and/or
dermis with subsequent regrowth of these layers. Chemical peels are divided into superficial
(light), medium, and deep; with superficial peels being the focus of this study. Superficial
peels penetrate into the epidermis only, and are a safe, widely available and well-tolerated
treatment modality. These peeling agents include glycolic acid, lactic acid, mandelic acid,
salicylic acid and trichloroacetic acid, each with unique properties. For instance,
alpha-hydroxy acids, such as glycolic acid, are known to be hydrophilic, whereas salicylic
acid is lipophilic and anti-inflammatory.
As each peeling agent has unique properties, it can be hypothesized that the combined use of
these agents may result in better clinical outcomes than the use of an agent alone. Prior
studies have demonstrated that the combined use of these peels are safe and effective in
improving a variety of skin conditions including acne scars, hyperpigmentation, and
infraorbital dark circles. Overall however, studies on the combined use of these chemical
peels in the treatment of melasma are lacking.
Therefore, the aim of this pilot study is to conduct a controlled comparison of the efficacy
and safety of a combination peel (glycolic acid and salicylic acid) as compared to glycolic
acid peel alone in the treatment of melasma.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05013801 -
A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma
|
N/A | |
Recruiting |
NCT06174545 -
Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma
|
N/A | |
Completed |
NCT01695356 -
Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma
|
Phase 4 | |
Recruiting |
NCT06278948 -
Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma
|
N/A | |
Not yet recruiting |
NCT05911698 -
Fractional co2 Laser Followed by Either Vitamin c or Tranexamic Acid in Treatment of Melasma.
|
N/A | |
Recruiting |
NCT05656833 -
Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma
|
N/A | |
Recruiting |
NCT04597203 -
Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial
|
N/A | |
Completed |
NCT02138539 -
Evaluation of an Herbal-Based De-Pigmenting System
|
Phase 4 | |
Recruiting |
NCT01661556 -
Clinical Trial of Hydroquinone Versus Miconazol in Melasma
|
Phase 4 | |
Completed |
NCT01001624 -
Melanil in the Treatment of Melasma
|
Phase 3 | |
Terminated |
NCT03415685 -
Lutronic PicoPlus Exploratory Clinical Trial
|
N/A | |
Recruiting |
NCT04765930 -
Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma
|
N/A | |
Completed |
NCT04137263 -
Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging
|
N/A | |
Recruiting |
NCT03686787 -
Oral Tranexamic Acid and Laser for Treatment of Melasma
|
Phase 4 | |
Completed |
NCT05969587 -
Cysteamine Compared to Hydroquinone in Melasma
|
Phase 3 | |
Completed |
NCT00472966 -
Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma
|
Phase 4 | |
Completed |
NCT00500162 -
Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma
|
Phase 4 | |
Completed |
NCT05884151 -
Comparison of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma
|
Phase 1 | |
Completed |
NCT05887219 -
Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma
|
Phase 1 | |
Recruiting |
NCT03308370 -
Platelet Rich Plasma in Treatment of Melasma
|
Phase 3 |